FDA Approves Eli Lilly's Jaypirca as First Line Treatment for Untreated CLL and SLL

On October 2, 2026, the U.S. Food and Drug Administration approved pirtobrutinib, which Eli Lilly and Company markets as Jaypirca, for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who have no known 17p deletion. The decision makes pirtobrutinib the first noncovalent Bruton tyrosine kinase inhibitor cleared in the initial treatment setting for this disease.

Chronic lymphocytic leukemia, or CLL, and small lymphocytic lymphoma, or SLL, are managed as a single disease. Eli Lilly said on October 2 that CLL accounts for about one quarter of new leukemia cases in the United States and that approximately 22,760 new cases of CLL will be diagnosed this year. The 17p deletion is a chromosomal change associated with unfavorable outcomes, and the company said approximately 92 percent to 95 percent of patients diagnosed with CLL do not carry it.

Pirtobrutinib blocks Bruton tyrosine kinase, an enzyme that malignant B cells rely on. Earlier drugs in this class bind the target covalently, forming a lasting bond, while pirtobrutinib binds noncovalently and reversibly. The FDA had already granted traditional approval to pirtobrutinib for adults with relapsed or refractory CLL or SLL after treatment with a covalent BTK inhibitor, and AJMC reported on October 2 that the first line indication arrived 10 months after that traditional approval, which converted a December 2023 accelerated approval.

The new clearance rests on BRUIN CLL-313, a randomized, open label, active controlled phase 3 trial registered as NCT05023980. The study enrolled 282 adults with previously untreated CLL or SLL without deletion of chromosome 17p and assigned them in a 1 to 1 ratio to pirtobrutinib at 200 milligrams orally once daily or to six cycles of bendamustine plus a rituximab product. An independent review committee assessed progression free survival as the main efficacy measure.

Key Facts

Eli Lilly announced on October 2 that the FDA approved an additional indication for Jaypirca, supplied as 100 milligram and 50 milligram tablets, for adult patients with previously untreated CLL or SLL with no known 17p deletion. The company called the drug the first and only approved noncovalent BTK inhibitor and said the approval allows its use as a first line treatment for appropriate patients. Jacob Van Naarden, executive vice president and president of Lilly Oncology, said the milestone underscores Jaypirca's versatility in the CLL continuum of care.

The U.S. Food and Drug Administration said on October 2, 2026, that efficacy was evaluated in 282 patients, with 141 assigned to pirtobrutinib and 141 to bendamustine plus rituximab. With an estimated median follow up of 28 months, median progression free survival was not estimable in the pirtobrutinib arm and was 33.5 months in the bendamustine plus rituximab arm, with a hazard ratio of 0.20, a 95 percent confidence interval of 0.11 to 0.37 and a p value below 0.0001.

Pharmacy Times reported on October 2 that 24 month progression free survival rates were 93.4 percent with pirtobrutinib and 70.7 percent with bendamustine plus rituximab. The overall response rate assessed by the independent review committee was 94 percent for pirtobrutinib, including a 13 percent complete response rate and an 81 percent partial response rate, compared with 81 percent for the comparison arm, which included a 21 percent complete response rate and a 60 percent partial response rate.

Overall survival data remained immature. The FDA said the median overall survival was not reached in either arm, with 13 deaths in total: three deaths, or 2.1 percent, in the pirtobrutinib arm and 10 deaths, or 7.1 percent, in the control arm. Pharmacy Times reported on October 2 that an interim overall survival analysis favored pirtobrutinib with a hazard ratio of 0.257 and a 95 percent confidence interval of 0.070 to 0.934, despite a 52.9 percent effective crossover rate.

On safety, serious adverse reactions occurred in 28 percent of patients taking pirtobrutinib, and those occurring in 3 percent or more of patients included pneumonia at 5 percent. All grade atrial fibrillation or flutter occurred in 1.4 percent, and patients with significant cardiovascular disease were excluded from the trial. The most common non laboratory adverse reactions were upper respiratory tract infection at 27 percent, rash at 22 percent and COVID-19 at 21 percent, while the most common grade 3 or 4 laboratory abnormality was decreased neutrophil count. Pharmacy Times reported on October 2 that pirtobrutinib produced fewer adverse event related dose reductions, 3.6 percent versus 31.1 percent, fewer grade 3 or higher treatment emergent adverse events, 40.0 percent versus 67.4 percent, and fewer discontinuations due to adverse events, 4.3 percent versus 15.2 percent. Labeling carries warnings for infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, hepatotoxicity and embryo fetal toxicity, and the recommended dose is 200 milligrams orally once daily until disease progression or unacceptable toxicity. Pirtobrutinib received orphan drug designation.

Analysis

The headline number is the hazard ratio of 0.20, but the more revealing figure is the 33.5 month median progression free survival in the control arm. Bendamustine plus rituximab is a genuine chemoimmunotherapy regimen, not a placebo, so a 0.20 hazard ratio means pirtobrutinib cut the relative risk of progression or death substantially against an active standard. At 24 months, 93.4 percent of patients on pirtobrutinib had not progressed versus 70.7 percent on chemoimmunotherapy, a gap large enough to reshape first line choices.

What this really means is that the first line conversation for CLL is shifting from a fixed course of chemoimmunotherapy to an oral therapy taken continuously until progression. The trial design makes the contrast explicit: six cycles of bendamustine plus rituximab versus daily pirtobrutinib for as long as it works. Median treatment duration for pirtobrutinib was 32 months, and 92 percent of patients receiving it were still on treatment beyond 24 months. A regimen that keeps working for years also keeps costing for years, which is why AJMC noted that continuous treatment duration may factor into payer and formulary assessments.

The safety data cut both ways. Fewer dose reductions, fewer grade 3 or higher treatment emergent events and fewer discontinuations favor pirtobrutinib over chemoimmunotherapy. Yet serious adverse reactions still occurred in 28 percent of patients, and the cardiac arrhythmia warning carries weight even at a 1.4 percent rate of all grade atrial fibrillation or flutter, particularly because the trial excluded patients with significant cardiovascular disease. Complete response rates were higher with bendamustine plus rituximab, 21 percent versus 13 percent, which shows that depth of response is not the same as durability of disease control.

The overall survival picture is still preliminary. Thirteen deaths across 282 patients is a small number, and the interim hazard ratio of 0.257 has a wide confidence interval of 0.070 to 0.934. The 52.9 percent crossover rate further complicates any survival comparison, because many control arm patients eventually received the drug under investigation. Progression free survival is conclusive and overall survival is promising but unfinished.

Why It Matters

The eligible population is large. Lilly said CLL accounts for about one quarter of new leukemia cases in the United States and that approximately 22,760 new CLL cases are expected this year. Since about 92 percent to 95 percent of newly diagnosed patients do not have a 17p deletion, the new indication touches the overwhelming majority of people starting treatment for this disease.

Guideline positioning reinforces the shift. Eli Lilly said Jaypirca is the first and only noncovalent BTK inhibitor recommended by the National Comprehensive Cancer Network, at Category 2A, for treatment naive adults with CLL or SLL without deletion of 17p, and AJMC reported on October 2 that same Category 2A listing. That tier places the drug inside the standard decision framework for newly diagnosed patients, which matters for community oncology practices that follow NCCN guidance closely.

Access and cost will decide how quickly the indication translates into practice. Pirtobrutinib is taken until progression, and median treatment duration in the trial was 32 months. Payer and formulary reviews will weigh that open ended duration against the 33.5 month median progression free survival seen with six cycles of bendamustine plus rituximab. The reimbursement argument will turn on budget impact as much as on hazard ratios.

Next Up

The immediate next step is mature overall survival data from BRUIN CLL-313. At the primary analysis, median overall survival had not been reached in either arm and only 13 deaths had occurred, so the interim hazard ratio of 0.257 is not yet definitive. Longer follow up will also clarify how the 52.9 percent crossover rate affects any survival comparison between the arms.

Beyond the trial, the practical test is adoption. Community oncologists and specialty pharmacists will weigh an oral therapy taken continuously against six cycles of chemoimmunotherapy, with attention to infection risk, cardiac monitoring and the warnings for hemorrhage, cytopenias, hepatotoxicity and embryo fetal toxicity. Payers will be watching how the 28 percent serious adverse reaction rate and the 32 month median treatment duration play out in real world use.